Travere Therapeutics recently received accelerated approval for Filspari (sparsentan) for the treatment of IgA Nephropathy (IgAN) and raised $200 million in a public offering. The company may struggle ...
TipRanks on MSN
Travere Therapeutics to present abstracts at ASN Kidney Week
Travere Therapeutics (TVTX) announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American ...
5d
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week ...
SAN DIEGO, June 03, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present seven abstracts at the upcoming European Renal Association (ERA) ...
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Travere Therapeutics' (NASDAQ:TVTX) oral medicine Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at ...
SAN DIEGO, September 10, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following ...
(RTTNews) - Travere Therapeutics Inc. (TVTX) said that the U.S. Food and Drug Administration granted accelerated approval to Filspari (sparsentan) to reduce proteinuria in adults with primary IgA ...
(RTTNews) - Travere Therapeutics Inc. (TVTX) announced that new data further demonstrates the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforces its potential in focal ...
Travere Therapeutics (TVTX) announced that the FDA has approved updated Risk Evaluation and Mitigation Strategy, or REMS, labeling for filspari – sparsentan -, the only Dual Endothelin Angiotensin ...
The update now reduces the frequency of liver function monitoring to every 3 months from the onset of treatment. The Food and Drug Administration (FDA) has updated the risk evaluation and mitigation ...
Novartis has spent considerable time and energy building its presence in the IgA nephropathy (IgAN) disease area, and now | ...
Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with FILSPARI and when FILSPARI is used in combination with SGLT2i New mechanistic data to show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results